Investigational drug · Phase 3
HSK31679
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis), Non-Alcoholic Steatohepatitis (NASH).
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "HSK31679"
First trial start
2024
Jan 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK31679", any sponsor or status.
Conditions studied
As listed on its trial records.
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- NASH (Non-Alcoholic Steatohepatitis)
- Non-Alcoholic Steatohepatitis (NASH)
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK31679" as an intervention, largest first.
- A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASHPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07581951 · 886 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 30, 2029
Drug: HSK31679; Placebo · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH (Non-Alcoholic Steatohepatitis)
Sites: Beijing, China
- Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)Pivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05795517 · 210 participants · Start Apr 26, 2023 · Primary completion Feb 20, 2024
Drug: HSK31679 low dose; HSK31679 medium dose and 3 more · For: Hypercholesterolemia
Sites: Beijing, China
- To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .Pivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06168383 · 186 participants · Start Jan 5, 2024 · Primary completion Dec 12, 2025
Drug: HSK31679 80mg; HSK31679 160mg and 1 more · For: Non-Alcoholic Steatohepatitis (NASH)
Sites: Beijing, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05531097 · 96 participants · Start Feb 22, 2022 · Primary completion Sep 21, 2022
Drug: HSK31679; Placebo · For: Healthy; Elevated LDL-C
Sites: Beijing, China; Changsha, China
- Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.Status unknown
Xizang Haisco Pharmaceutical Co., LtdIndustry
NCT06258746 · 6 participants · Start Dec 5, 2023 · Primary completion Dec 21, 2023
Drug: [14C]HSK31679 · For: Healthy
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Xue F, Liu J, Chen J, et al. · Lancet Gastroenterol Hepatol 2026
- Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial.
Xue F, Ma W, Gao J, et al. · Clin Gastroenterol Hepatol 2026
- Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids.
Zhang YH, Xie R, Dai CS, et al. · J Hepatol 2025
Also in development for MASH - Metabolic Dysfunction-Associated Steatohepatitis
- EfruxiferminPhase 33 trials
Akero Therapeutics, Inc · NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH
- HU6Phase 22 trials
Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- TGM-312-SC01Phase 21 trial
Tangram Therapeutics Plc · Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.